MacroGenics Inc (MacroGenics) is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. MacroGenics has entered into several strategic collaborations with global pharmaceutical and biotechnology companies to advance its proprietary programs. The company currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

MacroGenics's R&D arm focuses on the development of bispecific antibodies and T-cell engagers using its proprietary DART and TRIDENT platforms. The company has entered into strategic collaborations, such as with Gilead, to leverage these platforms for generating bispecific cancer antibodies. MacroGenics is also involved in developing antibody-drug conjugates and dual checkpoint inhibitors, aiming to improve the safety and efficacy of traditional T-cell engagers. The company's pipeline includes several clinical trials for product candidates targeting solid tumors and hematological malignancies. MacroGenics R&D activities are managed through its proprietary platforms, DART and TRIDENT, which are responsible for designing and developing multi-specific molecules that target multiple co-inhibitory receptors or checkpoints. These platforms enable the creation of potential medicines with enhanced biological effects and improved safety profiles. As of December 2025, MacroGenics held 58 patents in the United States with 24 patent applications pending, and 681 patents in other countries with 283 patent applications pending. The company's development pipeline includes product candidates such as retifanlimab, lorigerlimab, MGD024, MGC026, and MGC028, among others. MacroGenics has major technology alliances with companies like Gilead and Incyte, focusing on the development and commercialization of bispecific antibodies and monoclonal antibodies. In FY2025, the company spent US$147.2 million on R&D, which, as a percentage of revenue, stood at 98.5% and declined 17% YoY.